NASDAQ · NEO
Healthcare · Medical - Diagnostics & Research
$19.56
Down-$0.23 (-1.18%)
Updated Sep 25, 2026, 8:48 PM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
NEO closed at $19.56 after 20 trading sessions, up 4.94% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 24, 2026 | $18.47 | $19.73 | $18.40 | $19.56 | 2.95M |
| Sep 23, 2026 | $18.69 | $19.079 | $18.27 | $18.36 | 2.91M |
| Sep 22, 2026 | $19.28 | $19.60 | $18.83 | $18.89 | 4M |
| Sep 21, 2026 | $19.92 | $20.0499 | $19.28 | $19.41 | 1.44M |
| Sep 18, 2026 | $19.91 | $20.025 | $19.395 | $19.91 | 4.4M |
| Sep 17, 2026 | $19.11 | $19.89 | $18.98 | $19.89 | 2.01M |
| Sep 16, 2026 | $18.84 | $19.38 | $18.77 | $18.94 | 1.62M |
| Sep 15, 2026 | $18.40 | $19.29 | $18.40 | $18.89 | 2.43M |
| Sep 14, 2026 | $17.36 | $18.49 | $17.36 | $18.41 | 1.5M |
| Sep 11, 2026 | $17.85 | $17.92 | $17.21 | $17.32 | 1.07M |
| Sep 10, 2026 | $17.46 | $17.745 | $17.31 | $17.61 | 1.11M |
| Sep 9, 2026 | $17.28 | $17.995 | $17.15 | $17.66 | 1.54M |
| Sep 8, 2026 | $17.15 | $17.835 | $16.95 | $17.56 | 1.15M |
| Sep 4, 2026 | $17.20 | $17.47 | $16.865 | $17.38 | 997.01K |
| Sep 3, 2026 | $17.50 | $17.90 | $17.0542 | $17.46 | 2.25M |
| Sep 2, 2026 | $17.40 | $18.1763 | $17.26 | $17.40 | 1.79M |
| Sep 1, 2026 | $17.67 | $18.105 | $17.359 | $17.45 | 1.32M |
| Aug 31, 2026 | $17.77 | $18.075 | $17.19 | $17.91 | 1.58M |
| Aug 28, 2026 | $18.36 | $18.75 | $17.8938 | $18.05 | 1.72M |
| Aug 27, 2026 | $17.85 | $19.76 | $17.85 | $18.64 | 5.1M |
The latest Smart Investors Daily articles mentioning NEO.
NEO research
Company profile and research snapshot.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 29, 2026 | Needham | Buy | — |
| Jul 24, 2026 | Benchmark | Buy | — |
| Apr 29, 2026 | TD Cowen | Buy | — |
| Apr 29, 2026 | Benchmark | Buy | — |
| Apr 29, 2026 | Leerink Partners | Outperform | — |
Generated Sep 25, 2026, 5:14 PM
NeoGenomics shares declined 0.62% today amid broader healthcare sector scrutiny, as the company finds itself among stocks drawing investor skepticism. The modest pullback reflects cautious sentiment in the genomics and diagnostic testing space, with analysts taking a more critical stance on valuation and growth prospects.
Bottom line: Today's modest decline reflects skeptical analyst commentary on NEO alongside broader healthcare sector caution, but the move remains relatively contained. Investors should monitor whether this represents the start of a broader re-rating or merely a temporary pullback, while tracking company execution on profitability and the pipeline of cancer diagnostics innovation.
Yahoo · Sep 23, 2026
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 38.9% gain over the past six months, beating the S&P 500 by 20.9 percentage points.
Yahoo · Sep 22, 2026
What a time it’s been for NeoGenomics. In the past six months alone, the company’s stock price has increased by a massive 138%, reaching $19.30 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
Yahoo · Sep 22, 2026
NeoGenomics stock reaction to precision oncology expansion plan NeoGenomics (NEO) drew investor attention after executives detailed plans to expand in community-based precision oncology, highlighting next-generation sequencing, minimal residual disease testing, and workflow tools for community physicians as key focus areas. NeoGenomics shares have been on a strong run recently, with a 30-day share price return of 14.31% and a 90-day gain of 69.22%. The 1-year total shareholder return of...
Yahoo · Sep 21, 2026
Earlier in 2026, NeoGenomics executives detailed plans to expand in community-based precision oncology, with a particular push into next-generation sequencing, minimal residual disease testing, and workflow tools for community oncologists. An important takeaway is that NGS already represents a relatively small share of test volume but a much larger portion of clinical revenue, underscoring how mix shift toward advanced assays could reshape the company’s earnings profile. We’ll now examine...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NEO.
